ACRX

AcelRX Pharmaceuticals (ACRX)

AcelRX Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ACRX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/25	08 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/06/25	06 : 24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/04/30	05 : 25	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/04/30	05 : 24	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/04/30	05 : 23	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/04/20	05 : 37	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/03/22	05 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/03/16	05 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/03/13	07 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/01/09	23 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/01/09	23 : 05	PR Newswire (US)	AcelRx Announces Rebranding With Name Change to Talphera, Inc.	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/14	22 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/14	06 : 34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/14	06 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/12	22 : 30	PR Newswire (US)	AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/01	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/23	06 : 38	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/23	06 : 34	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/14	20 : 07	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/09	06 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/09	06 : 05	PR Newswire (US)	AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/08	06 : 05	PR Newswire (US)	AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/27	05 : 30	PR Newswire (US)	AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/21	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/11	05 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/06	05 : 45	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/06	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/03	21 : 30	PR Newswire (US)	AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/09/23	06 : 18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/09/12	08 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc